In current practice, direct application of the ASCO/CAP guidelines (developed for breast cancer) may yield different results compared to the adoption of the gynecologic-specific ISGyP criteria, particularly when defining the emerging therapeutic subgroup of HER2-low expression. The gene discussed is ERBB2; the disease is breast carcinoma.